{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:54:18Z","timestamp":1791028458516,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clml.2026.09.003","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:27:15Z","timestamp":1789086435000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Infection Prevention and Management in Patients With Multiple Myeloma Treated With Bispecific Antibodies: A Case-Based Approach for Routine Clinical Practice"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0945-0144","authenticated-orcid":false,"given":"Lorenzo","family":"Cani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Puppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Corcione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0948-9343","authenticated-orcid":false,"given":"Carmine","family":"Liberatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Mangiacavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Baril\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Giannella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3095-5313","authenticated-orcid":false,"given":"Ombretta","family":"Annibali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Girmenia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Veggia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Mina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.09.003_bib0001","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/hematology.2025000721","article-title":"CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma","volume":"2025","author":"Dima","year":"2025","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2026.09.003_bib0002","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Shah","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2026.09.003_bib0003","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood.2023021221","article-title":"CAR T-cell therapy in multiple myeloma: mission accomplished?","volume":"143","author":"Rasche","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.003_bib0004","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.clml.2024.11.012","article-title":"Comprehensive review of bispecific antibody constructs in multiple myeloma: affinities, dosing strategies and future perspectives","volume":"25","author":"Waldschmidt","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.09.003_bib0005","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.clml.2025.12.015","article-title":"Bispecific antibody therapy for multiple myeloma: a practical toolkit","volume":"26","author":"Rodriguez","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.09.003_bib0006","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.09.003_bib0007","first-page":"656","article-title":"Infection risk in 158 patients with relapsed\/refractory multiple myeloma treated with bispecific antibodies: a single-center experience","volume":"111","author":"Cani","year":"2026","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.09.003_bib0008","unstructured":"European Medicines Agency. Tecvayli: EPAR - Product Information; 2025. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecvayli-epar-product-information_en.pdf. Accessed June 19, 2026."},{"key":"10.1016\/j.clml.2026.09.003_bib0009","unstructured":"European Medicines Agency. Elrexfio: EPAR - Product Information; 2026. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/elrexfio-epar-product-information_en.pdf. Accessed June 19, 2026."},{"key":"10.1016\/j.clml.2026.09.003_bib0010","unstructured":"European Medicines Agency. Lynozyfic: EPAR - Product Information; 2025. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lynozyfic-epar-product-information_en.pdf. Accessed June 19, 2026."},{"key":"10.1016\/j.clml.2026.09.003_bib0011","unstructured":"European Medicines Agency. Talvey: EPAR - Product Information; 2025. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/talvey-epar-product-information_en.pdf. Accessed June 19, 2026."},{"key":"10.1016\/j.clml.2026.09.003_bib0012","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","article-title":"Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma","volume":"4","author":"Pillarisetti","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.09.003_bib0013","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.09.003_bib0014","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-026-04522-3","article-title":"FcRH5\u00d7CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial","author":"Cohen","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2026.09.003_bib0015","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2026.09.003_bib0016","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.09.003_bib0017","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","article-title":"Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma","volume":"42","author":"Garfall","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.09.003_bib0018","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2026.09.003_bib0019","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.136","article-title":"Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: update from the MagnetisMM-3 study","volume":"8","author":"Tomasson","year":"2024","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2026.09.003_bib0020","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.09.003_bib0021","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","article-title":"Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.09.003_bib0022","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.38961","article-title":"Kinetics of humoral immunodeficiency with bispecific antibody therapy in relapsed refractory multiple myeloma","volume":"5","author":"Hammons","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clml.2026.09.003_bib0023","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/bjh.19633","article-title":"Risk of infections with bispecific antibodies in B-cell non-Hodgkin lymphomas and multiple myeloma-the current state","volume":"205","author":"Gonugunta","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2026.09.003_bib0024","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.09.003_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2025.101287","article-title":"Practical guidance on the prevention and management of infection in multiple myeloma patients: a case-based approach","volume":"72","author":"Kannan","year":"2025","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2026.09.003_bib0026","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Infectious Diseases Society of America, clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2026.09.003_bib0027","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S1473-3099(25)00224-5","article-title":"Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study","volume":"25","author":"Maertens","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clml.2026.09.003_bib0028","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.3201\/eid2009.131668","article-title":"Pneumocystis jirovecii pneumonia in patients with or without AIDS, France","volume":"20","author":"Roux","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.clml.2026.09.003_bib0029","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.003_bib0030","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2026.09.003_bib0031","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1016\/j.clml.2025.11.004","article-title":"Linvoseltamab in patients with relapsed\/refractory multiple myeloma in the LINKER-MM1 study: longer follow-up and subgroup analyses","volume":"26","author":"Lee","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.09.003_bib0032","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/bloodadvances.2025016613","article-title":"Infections and parameters of humoral immunity with talquetamab in relapsed\/refractory multiple myeloma in MonumenTAL-1","volume":"9","author":"Schinke","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.09.003_bib0033","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clml.2026.09.003_bib0034","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.09.003_bib0035","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.2025029572","article-title":"Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs","volume":"147","author":"Jelinek","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.003_bib0036","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1182\/bloodadvances.2024013461","article-title":"Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma","volume":"8","author":"Ludwig","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.09.003_bib0037","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.09.003_bib0038","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1016\/S1473-3099(25)00069-6","article-title":"Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies","volume":"25","author":"Ljungman","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clml.2026.09.003_bib0039","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1093\/cid\/ciz1210","article-title":"Cytomegalovirus (CMV) cell-mediated immunity and CMV infection after allogeneic hematopoietic cell transplantation: the REACT study","volume":"71","author":"Chemaly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2026.09.003_bib0040","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2026.09.003_bib0041","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/TP.0000000000005374","article-title":"The Fourth International Consensus Guidelines on the Management of Cytomegalovirus in solid organ transplantation","volume":"109","author":"Kotton","year":"2025","journal-title":"Transplantation"},{"key":"10.1016\/j.clml.2026.09.003_bib0042","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.09.003_bib0043","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.09.003_bib0044","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","article-title":"Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network","volume":"35","author":"Ludwig","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.09.003_bib0045","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/ejh.70013","article-title":"Vaccination in multiple myeloma: challenges and strategies","volume":"115","author":"Martino","year":"2025","journal-title":"Eur J Haematol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2026.09.003_bib0046","doi-asserted-by":"crossref","first-page":"10073","DOI":"10.1182\/blood-2022-163733","article-title":"Infections and severe hypogammaglobulinemia in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"140","author":"Lancman","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.003_bib0047","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1182\/bloodadvances.2025016490","article-title":"Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels","volume":"9","author":"Banerjee","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.09.003_bib0048","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-025-01282-0","article-title":"Effect of intravenous immunoglobulin (IVIG) supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma","volume":"15","author":"Mohan","year":"2025","journal-title":"Blood Cancer J"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2026.09.003_bib0049","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1182\/blood-2024-205481","article-title":"Depletion of mature B cells and of normal plasma cells (PC) behind the higher incidence of infections after anti-BCMA vs anti-GPRC5D bispecific antibodies (bsAb) in relapsed refractory multiple myeloma (RRMM)","volume":"144","author":"Jelinek","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.003_bib0050","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.clml.2026.09.003_bib0051","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","article-title":"Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study","volume":"14","author":"Mohan","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.09.003_bib0052","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.clml.2025.10.024","article-title":"Preemptive immunoglobulin prophylaxis reduces infections in patients treated with anti-BCMA bispecific antibodies","volume":"26:","author":"Piron","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.09.003_bib0053","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-026-01451-9","article-title":"Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab","volume":"16","author":"Smits","year":"2026","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.09.003_bib0054","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.003_bib0055","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.clml.2024.05.002","article-title":"Risk of infection in patients with multiple myeloma treated with T-cell redirecting approaches: a call out for clinicians","volume":"24","author":"Lupia","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.09.003_bib0056","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.09.003_bib0057","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/bloodadvances.2021006178","article-title":"Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.09.003_bib0058","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2026.09.003_bib0059","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1016\/S2352-3026(25)00117-6","article-title":"Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network","volume":"12:","author":"van de Donk","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.09.003_bib0060","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1016\/j.clml.2025.12.003","article-title":"European expert recommendations on teclistamab management for relapsed or refractory multiple myeloma","volume":"26","author":"Rodriguez-Otero","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.09.003_bib0061","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciy866","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza","volume":"68","author":"Uyeki","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2026.09.003_bib0062","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.09.003_bib0063","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2026.09.003_bib0064","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/infdis\/jiy592","article-title":"The ability of a cytomegalovirus ELISPOT assay to predict outcome of low-level CMV reactivation in hematopoietic cell transplant recipients","volume":"219","author":"El Haddad","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clml.2026.09.003_bib0065","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/sj.bmt.1705825","article-title":"Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT","volume":"40","author":"Avetisyan","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2026.09.003_bib0066","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/bmt.2010.330","article-title":"Reconstitution of CMV pp65 and IE-1-specific IFN-\u03b3 CD8+ and CD4+ T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT","volume":"46","author":"Tormo","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 1","key":"10.1016\/j.clml.2026.09.003_bib0067","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood-2025-802","article-title":"Increased teclistamab dosing interval improves T-cell diversity and reduces infection risk, while T-cell exhaustion remains minimal irrespective of schedule","volume":"146","author":"Afrin","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2026.09.003_bib0068","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1182\/blood-2024-208192","article-title":"MagnetisMM-3: long-term update and efficacy and safety of less frequent dosing of elranatamab in patients with relapsed or refractory multiple myeloma","volume":"144","author":"Prince","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.003_bib0069","doi-asserted-by":"crossref","first-page":"e699","DOI":"10.1016\/j.clml.2026.03.003","article-title":"The evolution of chimeric antigen receptor T-cell, bispecific antibodies and antibody-drug conjugates for the treatment of multiple myeloma","volume":"26","author":"Cani","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"10.1016\/j.clml.2026.09.003_bib0070","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1182\/blood-2025-5814","article-title":"Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed\/refractory multiple myeloma","volume":"146","author":"Razzo","year":"2025","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026032891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026032891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:19:44Z","timestamp":1791026384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026032891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":70,"alternative-id":["S2152265026032891"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.09.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infection Prevention and Management in Patients With Multiple Myeloma Treated With Bispecific Antibodies: A Case-Based Approach for Routine Clinical Practice","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}